Figure 1



Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 394 11.0(10.1,12.4)
Motesanib 359 13.0(11.2,14.0)
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160 168 176 184
Weeks
Placebo (N) 549 508 451 398 347 294 250 198 161 128 110 97 84 75 68 56 43 27 17 10 2 0 0 0
Motesanib (N) 541 487 435 391 347 296 266 222 172 132 112 100 88 81 75 59 43 29 17 7 3 1 1 0

Figure 2



Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 451 5.4(4.7,5.5)
Motesanib 389 5.6(5.4,6.2)
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160
Weeks
Placebo (N) 549 415 321 208 96 63 35 23 13 10 9 7 5 3 3 2 1 0 0 0 0
Motesanib (N) 541 426 324 220 122 74 48 33 22 16 13 11 10 7 6 6 4 1 1 1 0

Figure 3



Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 76 15.5(10.8,19.3)
Motesanib 56 20.9(15.4,30.0)
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Weeks
Placebo (N) 112 108 91 75 65 55 42 31 28 26 22 9 3 0
Motesanib (N) 107 101 100 89 79 60 43 36 33 30 27 14 5 0

Figure 4




Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 96 4.5(3.9,5.7)
Motesanib 80 7.0(5.8,7.9)
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136
Weeks
Placebo (N) 112 83 63 41 20 13 9 4 1 1 1 1 1 0 0 0 0 0
Motesanib (N) 107 98 81 60 33 22 14 9 6 5 4 3 2 2 2 2 1 0

Figure 5



Placebo (N)	437	381	307	245	185	121	86	70	56	47	34	28	14	5	0	0
Motesanib (N)	434	355	291	235	187	135	89	68	55	47	32	20	12	4	1	0

Figure 6



Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 355 5.4(4.8,5.6)
Motesanib 309 5.5(4.8,5.7)
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160
Weeks
Placebo (N) 437 332 258 167 76 50 26 19 12 9 8 6 4 3 3 2 1 0 0 0 0
Motesanib (N) 434 328 243 160 89 52 34 24 16 11 9 8 8 5 4 4 3 1 1 1 0

Figure 7



Figure 14a-2.1 Progression Free Survival
Non-Squamous Full Analysis Set (Asia Only)
Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 101 5.3(4.0,5.7)
Motesanib 84 7.0(5.8,7.9)
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160 168
Weeks
Placebo (N) 117 88 68 44 22 15 9 4 1 1 1 1 1 0 0 0 0 0 0 0 0 0
Motesanib (N) 110 101 83 62 34 23 15 10 7 6 4 3 2 2 2 2 2 2 2 2 2 0

Figure 8



Figure 14a-1.1 Overall Survival
Non-Squamous Full Analysis Set (Asia Only)
Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 92 14.9(10.8,18.9)
Motesanib 71 21.1(15.4,30.0)
0 16 32 48 64 80 96 112 128 144 160 176 192 208
Weeks
Placebo (N) 117 104 84 68 58 48 39 30 20 19 16 1 0 0
Motesanib (N) 110 104 94 81 68 58 48 33 28 24 21 10 1 0

Figure 9




Figure 14j-1.1 Overall Survival
Non-Squamous Full Analysis Set (Japan Only)
Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 35 20.7(13.5,27.4)
Motesanib 32 26.7(16.3,37.1)
0 16 32 48 64 80 96 112 128 144 160 176 192
Weeks
Placebo (N) 51 49 46 38 32 29 22 17 10 10 9 0 0
Motesanib (N) 56 55 49 42 39 34 29 20 16 13 12 5 0

Figure 10


Figure 14j-2.1 Progression Free Survival
Non-Squamous Full Analysis Set (Japan Only)
Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 40 5.8(4.2,7.0)
Motesanib 40 7.1(6.7,8.8)
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160 168
Weeks
Placebo (N) 56 42 34 23 11 6 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Motesanib (N) 56 53 43 37 17 13 8 6 5 4 2 2 2 2 2 2 2 2 2 2 2 0